(for example,chemotherapy drugsandblood, and so on) come into contact with auxiliary [...] legco.gov.hk legco.gov.hk 報道更指溶脂性高的液體(例如化療用藥劑和血液等)接觸含PVC質料的輔助醫療器材後會釋出更多塑化劑,經這 些醫療器材輸入體內,後果較進食受塑化劑污染的食品更嚴重,對早 產嬰兒、長期病...
Purpose of Review With the recent approval of multiple new drugs for the treatment of acute myeloid leukemia (AML), the relevance of conventional treatment approaches, such as daunorubicin and cytarabine ("3+7") induction chemotherapy, has been challenged. We review the AML risk stratification, ...
Incorporation of new targeted agents, such as tyrosine kinase and small-molecule inhibitors, combined with better selection of drugs for unique patient cohorts, will likely be necessary to substantially improve outcomes in AML.doi:10.1517/14656566.2015.1076795Lynch RC...
The FDA has approved quizartinib (Vanflyta) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3...
1. FDA approves quizartinib for newly diagnosed acute myeloid leukemia. News release. July 20, 2023. Accessed July 20, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia 2. Erba HP, Monetesinos P, Kim HJ, et al. Qui...
Combo Tx for AML Patients Unfit for Intensive Chemotherapy Gets FDA Breakthrough StatusLea EslavaKimPharmD
Furthermore, it is at diagnosis, secondary vs de novo AML, cytogenetic risk and conceivable that outcomes with IC may improve significantly with NPM1/FLT3-ITD mutations) [9]. According to guidelines, missing the advent of recently approved drugs that may limit early toxicity values were imputed...
It has been noted that drugs can be concentrated in the eccrine glands.1-3 Accumulation of a chemotherapy agent or its toxic metabolite in the eccrine gland and subsequent excretion in sweat may explain the striking clinical distribution of this eruption to natural sites of occlusion. We hypothesi...
Midostaurin was found to synergize with standard chemotherapeutic drugs and some targeted agents against AML cells without mutations in FLT3. The mechanism may involve, in part, the unique kinase profile of midostaurin that includes proteins implicated in AML transformation, such as SYK or KIT, or ...
Monitor patients for increased risk of QTc interval prolongation. Strong CYP3A4 Inducers: Avoid concomitant use with TIBSOVO. Sensitive CYP3A4 Substrates: Avoid concomitant use with TIBSOVO. QTc Prolonging Drugs: Avoid concomitant use with TIBSOVO. If co-administration is unavoidable, monitor patients ...